Tags

Type your tag names separated by a space and hit enter

Involvement of the fas system in hepatitis C virus recurrence after liver transplantation.
Liver Transpl. 2000 Sep; 6(5):562-9.LT

Abstract

To date, there have been no reports of the involvement of the Fas system in recurrent hepatitis C virus (HCV) infection after orthotopic liver transplantation (OLT). In 25 patients who underwent OLT for HCV-related liver cirrhosis, we evaluated the expression of the Fas antigen (FasAg) on hepatocytes, apoptic hepatocytes, and serum levels of soluble Fas (sFas). The level of HCV viremia and HCV genotype were determined by polymerase chain reaction. Serum sFas levels were determined by an enzyme immunoassay procedure. DNA fragmentation was determined by the terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick end-labeling (TUNEL) technique on deparaffinized liver samples. FasAg expression was evaluated by an immunoperoxidase method. Sixteen patients had evidence of recurrent HCV disease. The number of hepatocytes expressing FasAg and the percentage of apoptotic hepatocytes was greater among patients who developed recurrent hepatitis than among those who did not (P <.01 and P <.0001, respectively). There was a correlation between hepatic expression of FasAg, intensity of lobular inflammation (P =.007), and TUNEL index (P <.001). The levels of sFas were greater among the patients with recurrent HCV hepatitis than those without recurrent hepatitis (P <.04). We conclude that (1) Fas expression is up-regulated in recurrent HCV after OLT and is related to the grading of liver disease; likewise, levels of sFas were greater in the patients with recurrent HCV hepatitis; and (2) the demonstration of hepatocytes with FasAg expression and the labeling of the nuclei by TUNEL assay suggest that hepatic apoptosis mediated by the Fas system may have a role in the pathogenesis of recurrent HCV hepatitis after OLT.

Authors+Show Affiliations

Gastroenterology and Hepatology Unit, University Hospital Marques de Valdecilla, Santander, Spain. javiercrespo@teleline.esNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

10980054

Citation

Crespo, J, et al. "Involvement of the Fas System in Hepatitis C Virus Recurrence After Liver Transplantation." Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, vol. 6, no. 5, 2000, pp. 562-9.
Crespo J, Rivero M, Mayorga M, et al. Involvement of the fas system in hepatitis C virus recurrence after liver transplantation. Liver Transpl. 2000;6(5):562-9.
Crespo, J., Rivero, M., Mayorga, M., Fabrega, E., Casafont, F., Gomez-Fleitas, M., & Pons-Romero, F. (2000). Involvement of the fas system in hepatitis C virus recurrence after liver transplantation. Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 6(5), 562-9.
Crespo J, et al. Involvement of the Fas System in Hepatitis C Virus Recurrence After Liver Transplantation. Liver Transpl. 2000;6(5):562-9. PubMed PMID: 10980054.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Involvement of the fas system in hepatitis C virus recurrence after liver transplantation. AU - Crespo,J, AU - Rivero,M, AU - Mayorga,M, AU - Fabrega,E, AU - Casafont,F, AU - Gomez-Fleitas,M, AU - Pons-Romero,F, PY - 2000/9/9/pubmed PY - 2000/10/21/medline PY - 2000/9/9/entrez SP - 562 EP - 9 JF - Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society JO - Liver Transpl. VL - 6 IS - 5 N2 - To date, there have been no reports of the involvement of the Fas system in recurrent hepatitis C virus (HCV) infection after orthotopic liver transplantation (OLT). In 25 patients who underwent OLT for HCV-related liver cirrhosis, we evaluated the expression of the Fas antigen (FasAg) on hepatocytes, apoptic hepatocytes, and serum levels of soluble Fas (sFas). The level of HCV viremia and HCV genotype were determined by polymerase chain reaction. Serum sFas levels were determined by an enzyme immunoassay procedure. DNA fragmentation was determined by the terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick end-labeling (TUNEL) technique on deparaffinized liver samples. FasAg expression was evaluated by an immunoperoxidase method. Sixteen patients had evidence of recurrent HCV disease. The number of hepatocytes expressing FasAg and the percentage of apoptotic hepatocytes was greater among patients who developed recurrent hepatitis than among those who did not (P <.01 and P <.0001, respectively). There was a correlation between hepatic expression of FasAg, intensity of lobular inflammation (P =.007), and TUNEL index (P <.001). The levels of sFas were greater among the patients with recurrent HCV hepatitis than those without recurrent hepatitis (P <.04). We conclude that (1) Fas expression is up-regulated in recurrent HCV after OLT and is related to the grading of liver disease; likewise, levels of sFas were greater in the patients with recurrent HCV hepatitis; and (2) the demonstration of hepatocytes with FasAg expression and the labeling of the nuclei by TUNEL assay suggest that hepatic apoptosis mediated by the Fas system may have a role in the pathogenesis of recurrent HCV hepatitis after OLT. SN - 1527-6465 UR - https://www.unboundmedicine.com/medline/citation/10980054/Involvement_of_the_fas_system_in_hepatitis_C_virus_recurrence_after_liver_transplantation_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1527646500441183 DB - PRIME DP - Unbound Medicine ER -